MedTrace Logo

Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension

NCT01122251 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 441

Last updated 2011-02-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure. The study will investigate the dose response relationship for the combinations and monotherapies.

Conditions

  • Essential Hypertension

Interventions

DRUG

Lercanidipine + Valsartan

L10/V80, L20/V80, L10/V160, L20/V160

DRUG

Lercanidipine or Valsartan

L10, L20, V80, V160

DRUG

Placebo

Placebo of Lercanidipine and Valsartan

Sponsors & Collaborators

  • LG Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-05-31
Completion
2010-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01122251 on ClinicalTrials.gov